Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant ipilimumab vs placebo after complete resection of high‑risk stage III melanoma
2007-001974-10Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Ipilimumab with Placebo (2 arms). Primary endpoints: Recurrence-free survival and Overall survival. Started Jun 2008; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-001974-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001974-10.